

James B Lorens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5641588/publications.pdf>

Version: 2024-02-01

137
papers

5,256
citations

109321

35
h-index

91884

69
g-index

144
all docs

144
docs citations

144
times ranked

8112
citing authors

#	ARTICLE	IF	CITATIONS
1	C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. <i>Nature Communications</i> , 2022, 13, 69.	12.8	16
2	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	6.5	29
3	Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 841447.	3.9	17
4	Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models. <i>Frontiers in Oncology</i> , 2022, 12, 818437.	2.8	7
5	Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. <i>Frontiers in Immunology</i> , 2022, 13, 869676.	4.8	24
6	MO434: Bemcentinib Targets Macrophage and Mesangial Cells in Renal Fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
7	Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021, 13, 941.	3.7	20
8	High-dimensional immunotyping of tumors grown in obese and non-obese mice. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	7
9	AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1412-1421.	3.4	16
10	Axlinhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7407-7417.	3.6	11
11	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6749-6760.	7.0	39
12	AXL Inhibition Represents a Novel Therapeutic Approach in Negative Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e630.	2.7	0
13	Phosphatidylserine receptors enhance SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2021, 17, e1009743.	4.7	55
14	AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e630.	2.7	2
15	AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. <i>Physiological Reports</i> , 2021, 9, e15140.	1.7	5
16	A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 349-368.	4.5	39
17	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. <i>IScience</i> , 2020, 23, 101649.	4.1	20
18	Editorial: Targeting the Tumor Microenvironment for a More Effective and Efficient Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 933.	4.8	3

#	ARTICLE	IF	CITATIONS
19	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999.	1.1	66
20	Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. <i>Gastric Cancer</i> , 2020, 23, 824-836.	5.3	25
21	362â€¦A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. , 2020, 8, A387-A387.		2
22	Decoding cancerâ€™s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
23	The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408). <i>Blood</i> , 2020, 136, 14-14.	1.4	3
24	A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 185, 57-70.	2.5	5
25	AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. <i>Cancer Immunology Research</i> , 2019, 7, 1789-1802.	3.4	52
26	Adenoviral mediated mono delivery of BMP2 is superior to the combined delivery of BMP2 and VEGFA in bone regeneration in a critical-sized rat calvarial bone defect. <i>Bone Reports</i> , 2019, 10, 100205.	0.4	7
27	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer & Metabolism</i> , 2019, 7, 6.	5.0	51
28	AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction. <i>Physiological Reports</i> , 2019, 7, e14091.	1.7	13
29	Identifying Lysophosphatidic Acid Acyltransferaseâ€™ ² (LPAATâ€™ ²) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2. <i>ChemMedChem</i> , 2019, 14, 224-236.	3.2	13
30	A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nabpaclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS473-TPS473.	1.6	7
31	Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study. <i>Blood</i> , 2019, 134, 3943-3943.	1.4	1
32	Lower Cancer Incidenceâ€™Warfarin Effect or Immortal Time Bias?â€™Reply. <i>JAMA Internal Medicine</i> , 2018, 178, 585.	5.1	0
33	High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia. <i>Cell Reports</i> , 2018, 23, 1205-1219.	6.4	39
34	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 246-255.	0.9	127
35	Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 41.	3.7	22
36	Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS. <i>Blood</i> , 2018, 132, 2672-2672.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.. Journal of Clinical Oncology, 2018, 36, 3078-3078.	1.6	5
38	Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmacodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.. Journal of Clinical Oncology, 2018, 36, 7020-7020.	1.6	1
39	A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, 9548-9548.	1.6	3
40	The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.. Journal of Clinical Oncology, 2018, 36, 70-70.	1.6	1
41	Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.. Journal of Clinical Oncology, 2018, 36, TPS43-TPS43.	1.6	13
42	Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials.. Journal of Clinical Oncology, 2018, 36, 2559-2559.	1.6	1
43	A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.. Journal of Clinical Oncology, 2018, 36, e21043-e21043.	1.6	2
44	Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy. , 2018, , .		2
45	Microsphere cytometry to interrogate microenvironment-dependent cell signaling. Integrative Biology (United Kingdom), 2017, 9, 123-134.	1.3	3
46	Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. Oncoimmunology, 2017, 6, e1271858.	4.6	61
47	The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. , 2017, , 351-376.		2
48	Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Internal Medicine, 2017, 177, 1774.	5.1	63
49	Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. Physiological Reports, 2017, 5, e13305.	1.7	36
50	Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm, 2017, 8, 53-66.	3.4	12
51	Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models. , 2017, , .		5
52	Abstract CT056: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma. , 2017, , .		0
53	Abstract 3010: Broad reduction in cancer incidence in patients treated with warfarin: a prospective cohort study. , 2017, , .		0
54	Antiviral Screening of Multiple Compounds against Ebola Virus. Viruses, 2016, 8, 277.	3.3	37

#	ARTICLE	IF	CITATIONS
55	Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy. , 2016, , .		5
56	Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy. , 2016, , .		1
57	Abstract 5182: A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics using the tumor marker Rgs16::GFP. , 2016, , .		1
58	Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy. , 2016, , .		1
59	A new live-cell reporter strategy to simultaneously monitor mitochondrial biogenesis and morphology. Scientific Reports, 2015, 5, 17217.	3.3	19
60	The immortality two-step. Cell Cycle, 2015, 14, 798-798.	2.6	1
61	Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Research, 2015, 75, 3699-3705.	0.9	127
62	Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. Molecular Biology of the Cell, 2015, 26, 2698-2711.	2.1	12
63	Vimentin-mediated ERK Signaling Uncouples Slug Gene Regulatory Function. Cancer Research, 2015, 75, 2349-2362.	0.9	112
64	A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. DMM Disease Models and Mechanisms, 2015, 8, 1201-1211.	2.4	14
65	Abstract B78: Warfarin blocks Gas6-mediated Axl activation required for pancreatic tumor plasticity and metastasis. , 2015, , .		1
66	Automated Quantification and Integrative Analysis of 2D and 3D Mitochondrial Shape and Network Properties. PLoS ONE, 2014, 9, e101365.	2.5	55
67	Akt1 Activity Regulates Vessel Maturation in a Tissue Engineering Model of Angiogenesis. Tissue Engineering - Part A, 2014, 20, 2590-2603.	3.1	3
68	In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells. Leukemia Research and Treatment, 2014, 2014, 1-12.	2.0	11
69	Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics. Advanced Drug Delivery Reviews, 2014, 69-70, 123-131.	13.7	13
70	Flow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets. BMC Biotechnology, 2014, 14, 57.	3.3	1
71	Mesenchymal stem cells induce endothelial cell quiescence and promote capillary formation. Stem Cell Research and Therapy, 2014, 5, 23.	5.5	62
72	Age-Related Dysfunction in Mechanotransduction Impairs Differentiation of Human Mammary Epithelial Progenitors. Cell Reports, 2014, 7, 1926-1939.	6.4	74

#	ARTICLE	IF	CITATIONS
73	Effects of enoxaparin and dalteparin on proliferation and migration of patient-derived vascular smooth muscle cells. <i>Vasa - European Journal of Vascular Medicine</i> , 2014, 43, 124-131.	1.4	6
74	Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.. <i>Clinical Cancer Research</i> , 2014, 20, B30-B30.	7.0	3
75	Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies. <i>Cancer Research</i> , 2014, 74, 1747-1747.	0.9	11
76	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014, 124, 4512-4512.	1.4	1
77	Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. <i>Stem Cell Research and Therapy</i> , 2013, 4, 52.	5.5	36
78	Evaluating Extracellular Matrix influence on adherent cell signaling by Cold Trypsin Phosphorylation-specific Flow Cytometry. <i>BMC Cell Biology</i> , 2013, 14, 36.	3.0	13
79	Nitroreductase, a Near-Infrared Reporter Platform for <i>In Vivo</i> Time-Domain Optical Imaging of Metastatic Cancer. <i>Cancer Research</i> , 2013, 73, 1276-1286.	0.9	38
80	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. <i>Blood</i> , 2013, 122, 2443-2452.	1.4	178
81	Contextual Compound Screening for Improved Therapeutic Discovery. <i>ChemBioChem</i> , 2013, 14, 2512-2518.	2.6	7
82	Domains I and IV of Annexin A2 Affect the Formation and Integrity of In Vitro Capillary-Like Networks. <i>PLoS ONE</i> , 2013, 8, e60281.	2.5	14
83	p63 Attenuates Epithelial to Mesenchymal Potential in an Experimental Prostate Cell Model. <i>PLoS ONE</i> , 2013, 8, e62547.	2.5	31
84	The Tumor Microenvironment as a Transient Niche: A Modulator of Epigenetic States and Stem Cell Functions. , 2013, , 463-478.		2
85	Abstract C76: Axl signaling is required for stem cell traits and metastasis in breast cancer. , 2013, , .		0
86	Abstract 4888: Axl receptor signaling in required for stem cell traits and metastasis in breast cancer.. , 2013, , .		0
87	Abstract A095: The microenvironmental basis of AXL regulation. , 2013, , .		0
88	Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1469-1469.	1.4	0
89	Osteogenic stimulatory conditions enhance growth and maturation of endothelial cell microvascular networks in culture with mesenchymal stem cells. <i>Journal of Tissue Engineering</i> , 2012, 3, 204173141244323.	5.5	18
90	Image-Based High-Throughput Screening for Inhibitors of Angiogenesis. <i>Methods in Molecular Biology</i> , 2012, 931, 139-151.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Camptothecinâ€™ylâ€™methanthiole: Semisynthesis and Biological Evaluation. ChemMedChem, 2012, 7, 2134-2143.	3.2	18
92	A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5579-5583.	2.2	20
93	Soluble mediators released by acute myeloid leukemia cells increase capillaryâ€™like networks. European Journal of Haematology, 2012, 89, 478-490.	2.2	14
94	Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology, 2012, 28, 201-212.	5.3	8
95	S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. Oral Oncology, 2012, 48, 219-225.	1.5	40
96	Abstract 1290: The ability of the transcription factor p63 to induce selected gene expression modules associated with mesenchymal to epithelial transition of prostate cells. , 2012, , .		1
97	Abstract 3308: Axl is required for EMT-induced stem cell traits and metastasis in breast cancer. , 2012, , .		0
98	Efficient in vivo vascularization of tissue-engineering scaffolds. Journal of Tissue Engineering and Regenerative Medicine, 2011, 5, e52-e62.	2.7	49
99	Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1167-1170.	2.2	11
100	Abstract 3089: The role of p63 regulation during epithelial to mesenchymal transition (EMT) and subsequent accumulation of malignant features of primary immortalized prostate cells. , 2011, , .		0
101	A novel imagingâ€™based highâ€™throughput screening approach to antiâ€™angiogenic drug discovery. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 41-51.	1.5	32
102	Synthesis and biological evaluation of new camptothecin derivatives obtained by modification of position 20. Bioorganic and Medicinal Chemistry, 2010, 18, 8660-8668.	3.0	25
103	High content screening: seeing is believing. Trends in Biotechnology, 2010, 28, 237-245.	9.3	356
104	Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1124-1129.	7.1	503
105	Imaged-based High-Throughput Screening for Anti-Angiogenic Drug Discovery. Current Pharmaceutical Design, 2010, 16, 3958-3963.	1.9	27
106	Mural Cell Associated VEGF Is Required for Organotypic Vessel Formation. PLoS ONE, 2009, 4, e5798.	2.5	122
107	Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood, 2009, 114, 3439-3447.	1.4	298
108	Abstract B105: Axl is an essential epithelialâ€™toâ€™mesenchymal transitionâ€™induced regulator of breast cancer metastasis and patient survival. , 2009, , .		1

#	ARTICLE	IF	CITATIONS
109	Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. , 2009, , 193-203.		0
110	Enhanced gene expression from retroviral vectors. BMC Biotechnology, 2008, 8, 19.	3.3	3
111	Expanding the Spectrum of Genetic Elements Transferable by Retroviral Vectors. DNA and Cell Biology, 2007, 26, 773-779.	1.9	2
112	RNAi Screening for Therapeutic Targets in Human Malignancies. Current Pharmaceutical Biotechnology, 2007, 8, 337-343.	1.6	23
113	MicroRNAs in Tumorigenesis. Current Pharmaceutical Biotechnology, 2007, 8, 320-325.	1.6	50
114	Drug target discovery using retroviruses. Expert Opinion on Drug Discovery, 2007, 2, 1285-1300.	5.0	3
115	In Vivo Optical Imaging of Acute Myeloid Leukemia by Green Fluorescent Protein: Time-Domain Autofluorescence Decoupling, Fluorophore Quantification, and Localization. Molecular Imaging, 2007, 6, 7290.2007.00016.	1.4	29
116	The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology, 2007, 136, 814-828.	2.5	115
117	RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells. International Journal of Cancer, 2006, 120, 961-969.	5.1	7
118	Retroviral vectors to monitor somatic hypermutation. Journal of Immunological Methods, 2005, 300, 47-62.	1.4	4
119	Critical Role of the Ubiquitin Ligase Activity of UHRF1, a Nuclear RING Finger Protein, in Tumor Cell Growth. Molecular Biology of the Cell, 2005, 16, 5621-5629.	2.1	157
120	Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation. Cancer Research, 2005, 65, 9294-9303.	0.9	169
121	Cellular Localization and Antiproliferative Effect of Peptides Discovered from a Functionally Screened Retrovirally Delivered Random Peptide Library. Chemistry and Biology, 2003, 10, 975-987.	6.0	14
122	Activation of the PKB/AKT Pathway by ICAM-2. Immunity, 2002, 16, 51-65.	14.3	113
123	Intracellular protein scaffold-mediated display of random peptide libraries for phenotypic screens in mammalian cells. Chemistry and Biology, 2001, 8, 521-534.	6.0	45
124	The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics. Current Opinion in Biotechnology, 2001, 12, 613-621.	6.6	35
125	Dominant effector genetics in mammalian cells. Nature Genetics, 2001, 27, 23-29.	21.4	87
126	Salmon Eggshell Protein Expression: A Marker for Environmental Estrogens. Marine Biotechnology, 1999, 1, 252-260.	2.4	37

#	ARTICLE	IF	CITATIONS
127	Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293TCell-Based Systems. <i>Current Protocols in Immunology</i> , 1999, 31, Unit 10.17C.	3.6	223
128	A Novel Paired Domain DNA Recognition Motif Can Mediate Pax2 Repression of Gene Transcription. <i>Biochemical and Biophysical Research Communications</i> , 1999, 266, 532-541.	2.1	12
129	Toso, a Cell Surface, Specific Regulator of Fas-Induced Apoptosis in T Cells. <i>Immunity</i> , 1998, 8, 461-471.	14.3	210
130	Local Delivery of Interleukin 4 by Retrovirus-Transduced T Lymphocytes Ameliorates Experimental Autoimmune Encephalomyelitis. <i>Journal of Experimental Medicine</i> , 1997, 185, 1711-1714.	8.5	250
131	Molecular Cloning and Characterization of Anionic and Cationic Variants of Trypsin from Atlantic Salmon. <i>FEBS Journal</i> , 1995, 232, 677-685.	0.2	80
132	Molecular Cloning and Characterization of Anionic and Cationic Variants of Trypsin from Atlantic Salmon. <i>FEBS Journal</i> , 1995, 232, 677-685.	0.2	4
133	Pancreatic Carboxylester Lipase from Atlantic Salmon (<i>Salmo salar</i>). cDNA Sequence and Computer-Assisted Modelling of Tertiary Structure. <i>FEBS Journal</i> , 1994, 226, 603-612.	0.2	53
134	Biotechnology in Aquaculture, with Special Reference to Transgenic Salmon. <i>Biotechnology and Genetic Engineering Reviews</i> , 1993, 11, 33-56.	6.2	4
135	The Atlantic salmon prepro-gonadotropin releasing hormone gene and mRNA. <i>Molecular and Cellular Endocrinology</i> , 1992, 84, 167-174.	3.2	60
136	The complete nucleotide sequence of the Atlantic salmon growth hormone I gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1992, 1130, 345-348.	2.4	43
137	The nucleotide sequence of Atlantic salmon growth hormone cDNA. <i>Nucleic Acids Research</i> , 1989, 17, 2352-2352.	14.5	18